Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2024-12-11 Director's Dealing
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - Ms Cheryl Maley 2 pages 319.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in securities held by a director, including the number of shares and performance rights acquired and held before and after the change. The document is a formal notification of a director's personal share transactions, specifically the issuance of performance rights to the director. It does not contain financial statements or company-wide financial performance data. The document length is 3520 characters, which is consistent with a detailed director's dealing notice. Therefore, this document fits the category of Director's Dealing (DIRS).
2024-12-11 English
DEP Presentation at Radiopharmaceuticals Summit 30 pages 2.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation delivered at the 6th Targeted Radiopharmaceuticals Summit Europe by Starpharma, focusing on their DEP® dendrimer technology platform. It includes extensive scientific and technical information about the platform's capabilities, clinical validation, and potential applications in radiotheranostics. The content is structured as a presentation with slides, forward-looking statements, and detailed explanations of the technology, which aligns with the characteristics of an investor or scientific presentation rather than a formal regulatory filing or financial report. There is no indication that this is an annual report, earnings release, or regulatory filing. The document is not a brief announcement or a voting result. It is a comprehensive presentation aimed at investors and stakeholders to showcase the company's technology and pipeline. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-12-03 English
Results of 2024 Reconvened Annual General Meeting 2 pages 144.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement detailing the results of the 2024 reconvened Annual General Meeting (AGM) of Starpharma. It includes voting results for resolutions, references to the Corporations Act and ASX listing rules, and proxy voting details. The content focuses on the announcement of voting outcomes at the AGM rather than the full AGM materials or presentations. The document length is about 6,431 characters, which is consistent with a detailed announcement but not a full report or presentation. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-28 English
AGM Notice of Reconvened Meeting 2 pages 125.1KB
AGM Information Classification · 95% confidence The document is a notice regarding the reconvening of the Annual General Meeting (AGM) of Starpharma Holdings Limited. It discusses the adjournment and rescheduling of a vote on the Remuneration Report, provides details on how shareholders can participate, and references the original Notice of AGM and results of other resolutions. There is no detailed financial data, management discussion, or full report content present. The document is primarily an announcement related to the AGM event and voting process, not the AGM materials themselves or the full Annual Report. Therefore, it fits the category of AGM Information (AGM-R). The document length (6714 characters) supports it being a detailed notice rather than a brief announcement or a full report.
2024-11-26 English
AGM Chair's address and CEO's presentation 43 pages 2.7MB
AGM Information Classification · 100% confidence The document is an ASX announcement dated 26 November 2024, providing the Chair's address and CEO presentation for the Annual General Meeting (AGM) of Starpharma Holdings Limited. It includes detailed speeches, operational highlights, strategic priorities, and forward-looking statements typically presented at an AGM. The content is focused on shareholder communication during the AGM event, including presentations and addresses, rather than a full annual report or financial statements. The document length is substantial (15,000 characters), and it contains the actual text of the Chair's address and CEO presentation, not just an announcement of their availability. Therefore, this document fits the category of AGM Information (AGM-R).
2024-11-25 English
Results of 2024 Annual General Meeting 2 pages 150.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement detailing the results of the 2024 Annual General Meeting (AGM) of Starpharma. It includes voting results on various resolutions, references to the Corporations Act and ASX listing rules, and notes about an adjourned resolution. The content is focused on the official voting outcomes and procedural details of the AGM, not the full AGM materials or presentations. The document length is 7604 characters, which is sufficient to include detailed voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. It is not an Annual Report, Management Report, or Proxy Solicitation, nor is it a simple announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2024-11-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.